A composition of matter patent is the only piece of pharmaceutical intellectual property that a generic or biosimilar manufacturer cannot […]

The composition-of-matter patent is the loudest piece of intellectual property a pharmaceutical company owns. It is also, increasingly, the least

The Biologics Price Competition and Innovation Act turned fifteen years old in March, and the procedural ritual it created keeps

The pharmaceutical industry has always run on information asymmetry. The company that knows, six months before its competitors, that a

A practitioner’s guide for IP teams, generic manufacturers, and pharmaceutical investors who need to decode what a competitor’s formulation patent

There is a moment, familiar to every generic drug executive, when a promising target drug goes from ‘opportunity’ to ‘nightmare.’

The call came on a Tuesday morning. A general counsel at a mid-sized specialty pharma company had just received a

By the time a generic development team discovers that a drug’s composition-of-matter patent expires in three years, the real work

Every patent a pharmaceutical company files is a sworn, detailed confession. It tells you what the company’s chemists have been